United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
暂无分享，去创建一个
V. Sondak | J. Sosman | J. Kirkwood | F. Hodi | H. Kluger | Carrie Lee | L. Hutchins | M. Albertini | D. Lawrence | U. Rao | O. Hamid | D. Minor | G. Cohen | K. Kendra | L. Flaherty | A. Tarhini | Sandra J. Lee | T. Petrella | H. Koon